SCHEMBL4627827

SCHEMBL4627827

COC(=O)c1ccc(OC)c(NC(=N)c2ccc(F)cc2Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PYGL P06737 6/20 0.57
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
HDAC8 Q9BY41 4/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
KDM4E B2RXH2 2/20 0.48
CYP1A2 P05177 1/20 0.45
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4626798 0.88 CYP1A2 (0.50) PYGLSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL4627658 0.84 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1HPGDKDM4ECYP1A2
SCHEMBL4628276 0.81 TAS1R3 (0.52) SMN1; SMN2ALDH1A1HPGDHDAC8HDAC1
SCHEMBL4626818 0.79 RAB9A (0.51) PYGLSMN1; SMN2CYP1A2MAPTMEN1
SCHEMBL1554111 0.75 HDAC1 (0.58) ALDH1A1HPGDHDAC8HDAC1HDAC6
SCHEMBL4628354 0.75 HDAC8 (0.60) PYGLSMN1; SMN2ALDH1A1HDAC8HDAC1
SCHEMBL4628357 0.75 HDAC8 (0.60) PYGLSMN1; SMN2ALDH1A1HDAC8HDAC1
SCHEMBL13425100 0.75 MAPT (0.58) ALDH1A1HDAC8HDAC1HDAC6KDM4E
SCHEMBL1554272 0.75 MAPT (0.54) ALDH1A1HDAC8HDAC1HDAC6KDM4E
Hydrochloric Acid SCHEMBL1579963 0.74 HDAC1 (0.56) ALDH1A1HPGDHDAC8HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590333-A4 GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF CRYSTALGENOMICS INC (KR) 2008-04-30 EP disclosed
US-7179832-B2 Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof CRYSTALGENOMICS, INC. (KR) 2007-02-20 US disclosed
US-20060079521-A1 Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof CRYSTALGENOMICS, INC. (KR) 2006-04-13 US disclosed
EP-1590333-A1 GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF Crystalgenomics, Inc. (KR) 2005-11-02 EP disclosed
WO-2004065370-A1 GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF CRYSTALGENOMICS, INC. (KR) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079521-A1 Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof GSK3B, GSK3A, GYS2 PYGL 7/4885SMN1; SMN2 2993/4885ALDH1A1 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.